- Home
- ANAB vs NVRI Comparison
ANAB vs NVRI Comparison
Compare ANAB & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | NVRI |
|---|---|---|
| Founded | 2005 | 1853 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 996.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANAB | NVRI |
|---|---|---|
| Price | $49.06 | $18.10 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $59.90 | N/A |
| AVG Volume (30 Days) | 503.4K | ★ 2.4M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $169,467,000.00 | ★ $2,244,061,000.00 |
| Revenue This Year | $135.45 | N/A |
| Revenue Next Year | N/A | $3.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 196.42 | N/A |
| 52 Week Low | $12.21 | $4.72 |
| 52 Week High | $48.44 | $18.74 |
Technical Indicators
Market Signals| Indicator | ANAB | NVRI |
|---|---|---|
| Relative Strength Index (RSI) | 76.21 | 73.03 |
| Support Level | $43.92 | $17.69 |
| Resistance Level | $47.86 | $18.19 |
| Average True Range (ATR) | 2.33 | 0.27 |
| MACD | 0.19 | -0.21 |
| Stochastic Oscillator | 98.35 | 51.92 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.